Xenetic Biosciences Plc
| London Stock Exchange: XEN
Xenetic Biosciences Plc is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis in 1997 and is headquartered in London, the United Kingdom.